IONS

SEC source: 0000874015-17-000008 · edgar.xml · derivative · entry 14

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,013

Underlying: Common Stock · 163,013 shares

Expires 2024-01-02

F3 · derivative.exercise_date: Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 40,753 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017.

SEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 8

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 2,170

F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015.

F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015.

SEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 7

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 2,670

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015.

F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015.

SEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 6

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 2,170

F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015.

F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015.

SEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 5

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 2,670

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015.

F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015.

SEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 4

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,029

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

SEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 3

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,029

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

SEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,029

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

SEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,029

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

SEC source: 0000874015-17-000007 · edgar.xml · derivative · entry 2

Boyce Sarah · CIK 0001629383 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,225

Underlying: Common Stock · 45,225 shares

Expires 2024-01-02

F2 · derivative.exercise_date: Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 11,306 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017.

SEC source: 0000874015-17-000006 · edgar.xml · derivative · entry 3

Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,000

Underlying: Common Stock · 48,000 shares

Expires 2024-01-02

F3 · derivative.exercise_date: Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 12,000 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017.

SEC source: 0000874015-17-000006 · edgar.xml · nonDerivative · entry 2

Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,872

F2 · kind: Acquired as a result of shares owned under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2016. The sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 7/1/2014.

F2 · shares: Acquired as a result of shares owned under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2016. The sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 7/1/2014.

SEC source: 0000874015-17-000005 · edgar.xml · derivative · entry 2

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,225

Underlying: Common Stock · 45,225 shares

Expires 2024-01-02

F2 · derivative.exercise_date: Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 11,306 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017.

SEC source: 0000874015-17-000003 · edgar.xml · derivative · entry 2

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,225

Underlying: Common Stock · 45,225 shares

Expires 2024-01-02

F2 · derivative.exercise_date: Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 11,306 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017.

SEC source: 0000874015-17-000004 · edgar.xml · derivative · entry 2

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,225

Underlying: Common Stock · 45,225 shares

Expires 2024-01-02

F2 · derivative.exercise_date: Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 11,306 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017.

SEC source: 0000874015-17-000002 · edgar.xml · derivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,638

Underlying: Common Stock · 117,638 shares

Expires 2024-01-02

F2 · derivative.exercise_date: Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 29,410 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017.

SEC source: 0000874015-17-000001 · edgar.xml · derivative · entry 2

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,225

Underlying: Common Stock · 45,225 shares

Expires 2024-01-02

F2 · derivative.exercise_date: Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 11,306 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017.

SEC source: 0000874015-17-000007 · edgar.xml · nonDerivative · entry 1

Boyce Sarah · CIK 0001629383 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,130

F1 · kind: Reporting 992 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 992 shares may not be sold until July 2, 2017.

F1 · shares: Reporting 992 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 992 shares may not be sold until July 2, 2017.

SEC source: 0000874015-17-000006 · edgar.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,181

F1 · kind: Reporting 309 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 309 shares may not be sold until July 2, 2017.

F1 · shares: Reporting 309 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 309 shares may not be sold until July 2, 2017.

SEC source: 0000874015-17-000005 · edgar.xml · nonDerivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,950

F1 · kind: Reporting 424 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 424 shares may not be sold until July 2, 2017.

F1 · shares: Reporting 424 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 424 shares may not be sold until July 2, 2017.

SEC source: 0000874015-17-000003 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,014

F1 · kind: Reporting 211 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 211 shares may not be sold until July 2, 2017.

F1 · shares: Reporting 211 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 211 shares may not be sold until July 2, 2017.

SEC source: 0000874015-17-000004 · edgar.xml · nonDerivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,747

F1 · kind: Reporting 199 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These199 shares may not be sold until July 2, 2017.

F1 · shares: Reporting 199 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These199 shares may not be sold until July 2, 2017.

SEC source: 0000874015-17-000002 · edgar.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,864

F1 · kind: Reporting 171 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 171 shares may not be sold until July 2, 2017.

F1 · shares: Reporting 171 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 171 shares may not be sold until July 2, 2017.

SEC source: 0000874015-17-000001 · edgar.xml · nonDerivative · entry 1

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,157

F1 · kind: Reporting 640 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 640 shares may not be sold until July 2, 2017.

F1 · shares: Reporting 640 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 640 shares may not be sold until July 2, 2017.

SEC source: 0000874015-16-000152 · edgar.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,872

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 7/1/2014.

F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 7/1/2014.

SEC source: 0000874015-16-000151 · edgar.xml · derivative · entry 13

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By grandchild

Disclosed balance after: 0

Underlying: Common Stock · 1,000 shares

Expires 2019-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-16-000151 · edgar.xml · derivative · entry 12

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By son-in-law

Disclosed balance after: 0

Underlying: Common Stock · 1,000 shares

Expires 2019-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-16-000151 · edgar.xml · derivative · entry 11

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By daughter

Disclosed balance after: 0

Underlying: Common Stock · 1,000 shares

Expires 2019-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-16-000151 · edgar.xml · derivative · entry 10

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By daughter

Disclosed balance after: 0

Underlying: Common Stock · 1,000 shares

Expires 2019-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 8

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By grandchild

Disclosed balance after: 0

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

SEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 7

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By grandchild

Disclosed balance after: 1,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

SEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 6

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By son-in-law

Disclosed balance after: 0

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

SEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 5

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By son-in-law

Disclosed balance after: 1,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

SEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 4

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By daughter

Disclosed balance after: 0

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

SEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By daughter

Disclosed balance after: 1,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

SEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By daughter

Disclosed balance after: 0

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

SEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By daughter

Disclosed balance after: 1,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016.

SEC source: 0000874015-16-000150 · edgar.xml · derivative · entry 3

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500 shares

Expires 2017-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-16-000150 · edgar.xml · nonDerivative · entry 2

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,548

F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.

SEC source: 0000874015-16-000150 · edgar.xml · nonDerivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,048

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.

SEC source: 0000874015-16-000149 · edgar.xml · derivative · entry 3

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,344

Underlying: Common Stock · 350 shares

Expires 2020-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Grant of 1/2/2013 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/2/2014. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 1,875 shares per year. Following this transaction, the option was exercisable as to 2,187 on 12/5/2016.

SEC source: 0000874015-16-000149 · edgar.xml · nonDerivative · entry 2

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,526

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

SEC source: 0000874015-16-000149 · edgar.xml · nonDerivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,876

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

SEC source: 0000874015-16-000148 · edgar.xml · derivative · entry 5

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,410

Underlying: Common Stock · 12,500 shares

Expires 2020-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Grant of 1/30/2013 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/2/2014. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 15,570 shares per year. Following this transaction, the option was exercisable as to 9,815 on 12/1/2016.

SEC source: 0000874015-16-000148 · edgar.xml · nonDerivative · entry 4

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,693

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.60 to $43.50, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-16-000148 · edgar.xml · nonDerivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,193

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016.

SEC source: 0000874015-16-000148 · edgar.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,693

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $42.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-16-000148 · edgar.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,693

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016.

SEC source: 0000874015-16-000146 · edgar.xml · derivative · entry 6

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,694

Underlying: Common Stock · 806 shares

Expires 2020-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Grant of 1/2/2013 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/2/2014. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 1,875 shares per year. Following this transaction, the option was exercisable as to 2,381 on 11/14/2016.

SEC source: 0000874015-16-000146 · edgar.xml · derivative · entry 5

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,907

Underlying: Common Stock · 194 shares

Expires 2020-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Grant of 1/2/2013 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/2/2014. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 3,925 shares per year. Following this transaction, the option was exercisable as to 4,252 on 11/14/2016.